Asok Kumar Hiranandani, Chairman of Royal Group Holdings, says the carving up of its family business in 2011 was necessary for its succession and future expansion plans.
Wall Street expects flat earnings compared to the year-ago quarter on higher revenues when Newpark Resources (NR) reports results for the quarter ended March 2019. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 25. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.
Does the April share price for Saipem S.p.A. (BIT:SPM) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by estimating the company's future cash flows and discounting them to their present value. This is done using the Discounted Cash Flow (DCF) model.
Shares of Sleep Number (NASDAQ: SNBR) were sinking today after the mattress maker missed top-line estimates in its earnings report, and the company failed to raise its earnings outlook despite a strong bottom-line result. Sleep Number said comparable sales rose 5% in the first quarter, which along with new stores drove overall revenue up 10% to $426.4 million. CEO Shelly Ibach said, "Sleep Number 360 smart beds, which are providing our customers with life-changing sleep, drove record first-quarter sales and EPS.
Nasdaq President Nelson Griggs joins Yahoo Finance's Julie Hyman and Adam Shapiro to talk about the 2019 IPO rush and what we can expect for the rest of the year.
While many biopharmaceutical companies have partnerships or collaborations with one or two larger companies, Inovio Pharmaceuticals has product development deals in place with more than a half dozen pharmaceutical and biotech firms and research organizations inside and outside the United States. Inovio is in that position largely because it is developing a technology platform with two parts that can be applied to a variety of medical conditions. The second part is the system for delivering the therapy through the skin or into muscle tissues using brief and low voltage electronic pulses. That standing, said Inovio co-founder and CEO J. Joseph Kim, gives the Plymouth Meeting-based company different aspirations than other development-stage drug developers.
Shares of Brazilian fintech company StoneCo (NASDAQ: STNE), which gained notoriety in recent months after being added to Berkshire Hathaway's portfolio, are plummeting today. Generally speaking, moves like this are often seen after earnings announcements, but StoneCo isn't set to report earnings again for another couple months. In this case, the plunge appears to be triggered by a move from a rival company.
What happened Shares of Amyris (NASDAQ: AMRS) jumped nearly 23% today after the company announced the preliminary details of a long-awaited financial transaction with a major technology licensee and shareholder. The synthetic biology pioneer's technology is used to manufacture a key chemical precursor to vitamin E, which allowed it to receive royalties from DSM (a Dutch multinational active in the fields of health, nutrition, and materials) on vitamin E sales. The pair have agreed to simplify the arrangement.
Comcast's NBCUniversal said it's achieved a "true first" for its industry on Tuesday, when it announced it will lead a new partnership with the host committees of the 2028 Olympic and Paralympic games in Los Angeles that will centralize all Olympic ad spending. The deal was inked with the LA 2028 Organizing Committee and the U.S. Olympic Committee — which have already partnered up on ad and sponsorship sales — and will create a "single point of entry" for all brands looking to get a piece of the games' buzz, reach and vast audience. While the agreement is anchored by the 2028 games, its terms span the seven years leading up to it, beginning in 2021 and covering four Olympic and Paralympic games.
Don't expect Boeing Co. to face a slew of order cancellations following the 737 Max debacle. Airlines, Boeing's (BA) main customers, are hungry for fuel-efficient single-aisle aircraft such as the Max, and there's a long backlog for the jet's closest competitor, Airbus SE' (FR:AIR) A320neo, analysts at Oxford Economics said in a note Thursday. “That will shield Boeing from a mass cancellation of orders,” the analysts said.
What happened Shares of Nintendo (NASDAQOTH: NTDOY) were up 13.6% as of 1:30 p.m. EDT Thursday after news emerged that the company's Switch gaming console will soon begin selling in China. But Nintendo won't be selling the devices directly.
Marijuana stocks are among our top charts to watch today. Bank of America Merrill Lynch named the company as one of three marijuana stocks to buy. The stock, after sharp year-to-date gains, has been consolidating in recent weeks, but may be on the verge of its next leg up with cannabis stocks in general.
Shares of IT security specialist Check Point Software Technologies (NASDAQ: CHKP) plunged more than 11% in early trading on the Nasdaq today before retracing to about an 8.2% loss as of 12:40 p.m. EDT. Check Point reported its fiscal first-quarter 2019 earnings this morning, but earnings weren't the problem this time -- guidance was. An earnings beat could have sent Check Point stock up today.
Zoom and Pinterest both began trading on the public market today. Yahoo Finance's Zack Guzman and Kristin Myers are joined by Lauren Smith Brody, 'The Fifth Trimester' author and founder, and Barrett Daniels, Deloitte & Touche National IPO Services Leader, to discuss why both IPOs matter so much for valuations.
These Tech Stocks Could Be Overvalued at Their Current Prices(Continued from Prior Part)ZNGA's returns The stock of gaming company Zynga (ZNGA) has generated a return of 51% in the last 12 months. Since the start of 2019, the stock is up 36%.
What happened Shares of Tandem Diabetes Care (NASDAQ: TNDM) closed down 9.9% on Wednesday after sinking as much as 11.9% earlier in the day. There wasn't any negative news specific to the insulin pump maker. However, healthcare stocks overall took a beating on Wednesday amid increasing concerns about the political climate in Washington D.C., particularly with the Medicare for All plan proposed by presidential candidate Sen. Bernie Sanders (I-VT).
GE)'s beaten-down stock is up 25% year to date, and Melius Research analyst Scott Davis says the smartest industrial investor he knows is buying the shares. That's a tantalizing statement. Who is this investing star?
Mustang's shares are blasting off in response to the news that an experimental gene therapy, MB-107, for "bubble boy" disease -- also known as X-linked severe combined immunodeficiency, or XSCID for short -- reportedly cured eight boys with the deadly condition. Equally critical, Mustang said that the boys are showing no signs of unintended side effects from the therapy -- an issue that has derailed prior gene therapies for XSCID. Mustang licensed MB-107 from St. Jude Children's Research Hospital.
Pier 1 Imports Inc.'s Interim Chief Executive Cheryl Bachelder may have taken an optimistic tone after the home décor retailer reported disappointing fourth-quarter earnings, but analysts were bearish, bringing up the possibility of a liquidation in the not-so-distant future. “Given the trends in business, and its negative earnings per share, EBITDA [earnings before interest, tax, depreciation and amortization], and free cash flow, we see Pier 1 and its $1.6 billion in revenues as potentially at risk of needing liquidation if trends don't improve,” wrote KeyBanc Capital Markets analysts led by Bradley Thomas. KeyBanc thinks Kirkland's Inc. (KIRK) , Williams-Sonoma Inc. (WSM) , Bed Bath & Beyond Inc. (BBBY) and At Home Group Inc. (HOME) would benefit from a Pier 1 (PIR) liquidation.
The results met Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for earnings of 34 cents per share. The bank holding company posted revenue of $184.6 million in the period.
It is a pleasure to report that the Second Sight Medical Products, Inc. (NASDAQ:EYES) is up 34% in the last quarter. Indeed, the share price is down a whopping 80% in the last three years. Second Sight Medical Products isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS).
Shares of Blackstone Group (NYSE: BX) climbed nearly 7% on Thursday morning after the alternative asset manager reported first-quarter earnings that blew past expectations and announced plans to convert to a corporation from a partnership. Blackstone, before markets opened, said it had earned $0.71 per share in the first quarter, easily surpassing the consensus estimate for $0.53 per share in earnings. The partnership structure has prevented some classes of investors, namely pension funds and other tax-exempt institutions, from buying shares of Blackstone, and has made the company ineligible for inclusion on certain indexes.
Tesla is expected to report first-quarter results next Wednesday, April 24, with Wall Street bracing for a loss following two quarters of profits and hoping for better news on production and demand. The timing of the report is on the early side for Tesla, which typically reports its first-quarter numbers in early May, and it comes as the stock has been under pressure following a first-quarter delivery miss earlier this month. The report is also scheduled for release two days before an event aimed at showcasing Tesla's autonomous driving capabilities.
Companies like Cronos Group, which sports a $5.2 billion market cap, is only capable of perhaps 120,000 kilos of peak production, and is valued at north of 210 times forward earnings. Similarly, Aurora Cannabis, Canada's projected leading producer at 780,000 kilos a year at peak capacity, may not even be profitable in fiscal 2020 due to expansion costs. Yet it's lugging around an $8.5 billion valuation.
So what Skechers reported first-quarter revenue of $1.28 billion, up 2.1% year over year and $20 million below the average analyst estimate. Currency was a big problem during the quarter, knocking down sales by more than three percentage points. Adjusted for currency, Skechers' revenue rose 5.2%.
Kinder Morgan's (NYSE: KMI) first-quarter results came in about as expected. The solid start to 2019 has the company on pace to hit its full-year budget for cash flow. It also allowed Kinder Morgan to fulfill its promise to boost the dividend by 25%.